BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 30027617)

  • 1. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
    Wang Z; Wang Z; Zhang C; Liu X; Li G; Liu S; Sun L; Liang J; Hu H; Liu Y; Zhang W; Jiang T
    Cancer Sci; 2018 Sep; 109(9):2697-2705. PubMed ID: 30027617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma.
    Zhang C; Zhang Z; Li F; Shen Z; Qiao Y; Li L; Liu S; Song M; Zhao X; Ren F; He Q; Yang B; Fan R; Zhang Y
    Oncoimmunology; 2018; 7(11):e1461304. PubMed ID: 30377558
    [No Abstract]   [Full Text] [Related]  

  • 3. Correlation of immune phenotype with IDH mutation in diffuse glioma.
    Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
    Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A machine learning analysis of a "normal-like" IDH-WT diffuse glioma transcriptomic subgroup associated with prolonged survival reveals novel immune and neurotransmitter-related actionable targets.
    Nguyen HD; Allaire A; Diamandis P; Bisaillon M; Scott MS; Richer M
    BMC Med; 2020 Oct; 18(1):280. PubMed ID: 33059718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status.
    Li G; Wang Z; Zhang C; Liu X; Yang F; Sun L; Liang J; Hu H; Liu Y; You G; Bao Z; Zhang W; Wang Z; Jiang T
    Dis Markers; 2018; 2018():5975216. PubMed ID: 29887919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas.
    Wang Z; Liu X; Wang Z; Bao Z; Zhang W; Zhang C; Jiang T
    Curr Mol Med; 2018 Mar; 17(7):518-526. PubMed ID: 29437008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A five-microRNA signature for individualized prognosis evaluation and radiotherapy guidance in patients with diffuse lower-grade glioma.
    Zhang JH; Hou R; Pan Y; Gao Y; Yang Y; Tian W; Zhu YB
    J Cell Mol Med; 2020 Jul; 24(13):7504-7514. PubMed ID: 32412186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of DNA methylation in adult diffuse gliomas.
    Aoki K; Natsume A
    Brain Tumor Pathol; 2019 Apr; 36(2):84-91. PubMed ID: 30937703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phospholipase Cγ1 (PLCG1) overexpression is associated with tumor growth and poor survival in IDH wild-type lower-grade gliomas in adult patients.
    Li T; Yang Z; Li H; Zhu J; Wang Y; Tang Q; Shi Z
    Lab Invest; 2022 Feb; 102(2):143-153. PubMed ID: 34697421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
    Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
    Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation-mediated miR-155-FAM133A axis contributes to the attenuated invasion and migration of IDH mutant gliomas.
    Huang GH; Du L; Li N; Zhang Y; Xiang Y; Tang JH; Xia S; Zhang EE; Lv SQ
    Cancer Lett; 2018 Sep; 432():93-102. PubMed ID: 29885519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma.
    Zhou Z; Luther N; Ibrahim GM; Hawkins C; Vibhakar R; Handler MH; Souweidane MM
    J Neurooncol; 2013 Feb; 111(3):257-64. PubMed ID: 23232807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
    Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
    Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.
    Röver LK; Gevensleben H; Dietrich J; Bootz F; Landsberg J; Goltz D; Dietrich D
    EBioMedicine; 2018 Feb; 28():97-104. PubMed ID: 29396294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Type of IDH-wildtype Glioma Characterized by Gliomatosis Cerebri-like Growth Pattern, TERT Promoter Mutation, and Distinct Epigenetic Profile.
    Muench A; Teichmann D; Spille D; Kuzman P; Perez E; May SA; Mueller WC; Kombos T; Nazari-Dehkordi S; Onken J; Vajkoczy P; Ntoulias G; Bettencourt C; von Deimling A; Paulus W; Heppner FL; Koch A; Capper D; Kaul D; Thomas C; Schweizer L
    Am J Surg Pathol; 2023 Dec; 47(12):1364-1375. PubMed ID: 37737691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.